Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

313

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

December 31, 2012

Conditions
Progressive Supranuclear Palsy
Interventions
DRUG

Davunetide

Davunetide Nasal Spray 30 mg BID IN 52 weeks

DRUG

Placebo

Placebo Nasal Spray BID IN 52 weeks

Trial Locations (48)

3004

The Alfred Hospital, Melbourne

10032

Columbia University, New York

13353

Humboldt University Charité, Berlin

13385

Hopital Timone, Marseille

18147

Universität Rostock Zentrum für Nervenheilkunde und Poliklinik, Rostock

19104

University of Pennsylvania, Philadelphia

21287

John Hopkins Hospital, Baltimore

27599

Univeristy of North Carolina Department of Neurology, Chapel Hill

32224

Mayo Clinic, Florida, Jacksonville

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton

33612

The Frances J. Zesiewicz Foundation for Parkinson's Disease at USF, Tampa

34128

Paracelsus-Elena Klinik, Kassel

35039

Philipps Universität Marburg, Marburg

35294

University of Alabama - Birmingham, Birmingham

40202

University of Louisville Division of Movement Disorders, Louisville

44121

University Hospitals Case Medical CenterNI Movement Disorders Center, South Euclid

44791

Neurologisch Klinik der Ruhr-Universität im St. Josef-Hospital, Bochum

48109

University of Michigan Medical Center, Ann Arbor

55455

University of Minnesota Department of Neuology, Minneapolis

55905

Mayo Clinic, Rochester, MN, Rochester

60637

University of Chicago Medical Center, Chicago

66160

University of Kansas Medical Center Parkinson Disease & Movement Disorders Center, Kansas City

75013

Hôpitaux de Paris, Paris

75390

University of Texas Southwestern Medical Center, Dallas

77030

Baylor College of Medicine, Houston

80113

Colorado Neurological Institute - Rocky Mountain Movement Disorders Ctr, PC, Englewood

81377

Klinikum Großhadern, München

84108

University of Utah Center for Alzheimer's Care, Imaging &Research, Salt Lake City

85013

Muhammed Ali Parkinson Center and Movement Disorders Clinic, Phoenix

85259

Mayo Clinic, AZ, Scottsdale

87042

Limoges University Hospital, Limoges

89081

Universitäts- und Rehabilitationskliniken Ulm, Ulm

90033

USC Keck School of Medicine, Los Angeles

90095

David Geffen School of Medicine - UCLA, Los Angeles

92161

UCSD/VA Neurology Service, San Diego

94143

UCSF Memory and Aging Center, San Francisco

02115

Massachusetts General Hospital, Boston

01805

Lahey Clinic, Burlington

08901

UMDNJ - Robert Wood Johnson Medical Center, New Brunswick

N6A 5A5

London Sciences Health Center University Hospital, London

K1Y 4E9

Parkinson's Disease & Movement Disorders Clinic, Ottawa

M5T 2S8

Toronto Western Hospital University Health Network, Toronto

H2L 4M1

CHUM-Notre Dame Hospital Unité de Troubles du Mouvement, Montreal

H3G 1A4

McGill University Health Centre - Montreal General Hospital, Montreal

01307

Universitätsklinikum Carl Carus an der Technischen Universität, Dresden

RH16 4EX

Princess Royal Hospital, Haywards Heath

NE4 5PL

Clinical Ageing Research Unit (CARU) Newcastle University, Newcastle

M6 8HD

Greater Manchester Neuroscience Centre, Salford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allon Therapeutics

INDUSTRY

NCT01110720 - Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy | Biotech Hunter | Biotech Hunter